02:57 PM EST, 12/06/2024 (MT Newswires) -- Monopar Therapeutics ( MNPR ) shares were up more than 6% in recent Friday trading, a day after the company said the first cancer patient has been dosed in the company's therapeutic trial of MNPR-101-Lu.

The drug combines Monopar's antibody MNPR-101 with the therapeutic radioisotope lutetium-177, the company said.

MNPR-101 targets the urokinase plasminogen activator receptor, or uPAR, which is associated with highly malignant and metastatic cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.

Monopar said it found MNPR-101-Lu intravenous infusion to be well-tolerated with no serious adverse reactions.

Price: 22.31, Change: +1.31, Percent Change: +6.24